Cytovia

As of January 4, 2006, Cytovia, Inc. was acquired by EpiCept Corporation. Cytovia is a biopharmaceutical research company in the development stage, focused on the discovery and development of small molecule inhibitors and caspase activators. The company's apoptosis inhibitors, activators, and new drug modulation programs target programmed cell death. Its technology base includes patented drug candidates in the fields of oncology, oral mucositis, and cardiovascular diseases, as well as proprietary screening programs for other apoptosis-targeted drug candidates. The company was founded in 1997 and is headquartered in San Diego, California. It has been operating as a subsidiary of Maxim Pharmaceuticals since June 16, 2000.